Tumor infiltration by adoptively transferred T cells is independent of immunologic specificity but requires down-regulation of L-selectin expression

Journal of Immunology

Volumn 163, Issue 2, 1999, Pages 751-759

  Kjaergaard, Jørgen ^a   Shu, Suyu ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

L SELECTIN;

ADOPTIVE IMMUNOTHERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN SPECIFICITY; ARTICLE; CELL ISOLATION; CELL TRANSFER; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; TISSUE DISTRIBUTION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR REGRESSION;

EID: 0033565732     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Greenberger, P. D. 1991. Adoptive T-cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. Adv. Immunol. 49:281.
2. Shu, S., S. E. Strome, J. C. Krauss, G. E. Plautz, and A. E. Chang. 1994. Tumor-draining lymph nodes as a source for generating therapeutic immune T cells. In Immunotherapy of Cancer with Sensitized T Lymphocytes. A. E. Chang and S. Shu, eds. R. G. Landes Co., Austin, p. 1.
3. Shu, S., T. Chou, and S. A. Rosenberg. 1987. Generation from tumor-bearing mice of lymphocytes with in vivo therapeutic efficacy. J. Immunol. 139:295.
4. Chou, T., A. E. Chang, and S. Shu. 1988. Generation of therapeutic T lymphocytes from tumor-bearing mice by in vitro sensitization: culture requirements and characterization of immunologic specificity. J. Immunol. 140:2453.
5. Yoshizawa, H., K. Sakai, A. E. Chang, and S. Shu. 1991. Activation by anti-CD3 of tumor-draining lymph node cells for specific adoptive immunotherapy. Cell. Immunol. 134:473.
6. Wahl, W. L., J. J. Sussman, S. Shu, and A. E. Chang. 1994. Adoptive immunotherapy of murine intracerebral tumors with anti-CD3/interleukin-2-activated tumor-draining lymph node cells. J. Immunother. 15:242.
7. Peng, L., S. Shu, and J. C. Krauss. 1997. Treatment of subcutaneous tumor with adoptively transferred T cells. Cell. Immunol. 43:231.
8. Sakai, K., A. E. Chang, and S. Shu. 1990. Effector phenotype and immunologic specificity of T cell-mediated adoptive therapy for a murine tumor that lacks intrinsic immunogenicity. Cell. Immunol. 129:241.
9. Sussman, J. J., W. L. Wahl, A. E. Chang, and S. Shu. 1995. Unique characteristic associated with systemic adoptive immunotherapy of experimental intracerebral tumors. J. Immunother. 18:35.
10. Chang, A. E., S. Shu, T. Chou, R. Lafreniere, and S. A. Rosenberg. 1986. Difference in the effects of host suppression on the adoptive immunotherapy of subcutaneous and visceral tumors. Cancer Res. 46:3426.
11. Okada, K., U. Nannmark, N. L. Vujanovic, S. Watkins, P. Basse, R. B. Herberman, and T. L. Whiteside. 1996. Elimination of established liver metastases by human interleukin 2-activated natural killer cells after locoregional or systemic adoptive transfer. Cancer Res. 56:1599.
12. Basse, P., R. B. Herberman, U. Nannmark, B. R. Johansson, M. Hokland, K. Wasserman, and R. H. Goldfarb. 1991. Accumulation of adoptive transferred adherent, lymphokine-activated killer cells in murine metastases. J. Exp. Med. 174:479.
13. Kjaergaard, J., M. Hokland, U. Nannmark, P. Hokland, and P. Basse. 1998. Infiltration patterns of short-and long-term cultured A-NK and T-LAK cells following adoptive immunotherapy. Scand. J. Immunol. 47:532.
14. Rosenberg, S. A., P. Spiess, and R. Lafreniere. 1986. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 233:1318.
15. Wallace, P. K., L. D. Palmer, D. Perry-Lalley, E. S. Bolton, R. B. Alexander, P. K. Horan, J. C. Yang, and K. A. Muirhead. 1993. Mechanisms of adoptive immunotherapy: improved methods for in vivo tracking of tumor-infiltrating lymphocytes and lymphokine-activated killer cells. Cancer Res. 53:2358.
16. Matsumura, T., J. J. Sussman, R. A. Krinock, A. E. Chang, and S. Shu. 1994. Characteristic and in vivo homing of long-term T-cell lines and clones derived from tumor-draining lymph nodes. Cancer Res. 54:2744.
17. Kagamu, H., J. E. Touhalisky, G. E. Plautz, J. C. Krauss, and S. Shu. 1996. Isolation based on L-selectin expression of immune effector cells derived from tumor-draining lymph nodes. Cancer Res. 56:4338.
18. low cells promotes the generation of highly potent CD4 antitumor effector T lymphocytes. J. Immunol. 160:3444.
19. Wexler, M. 1966. Accurate identification of experimental pulmonary metastases. J. Natl. Cancer Inst. 36:641.
20. Yoshizawa, H., A. E. Chang, and S. Shu. 1992. Cellular interaction in effector cell generation and tumor regression mediated by anti-CD3/interleukin 2-activated tumor-draining lymph node cells. Cancer Res. 52:1129.
21. Bevilacqua, M. P., and R. M. Nelson. 1993. Selectins. J. Clin. Invest. 91:379.
22. Kishimoto, T. K., M. A. Julita, E. L. Berg, and E. C. Butcher. 1989. Neutrophil Mac-1 and MEL-14 adhesion proteins inversely regulated by chemotactic factors. Science 245:1238.
23. Sasaki, A., R. K. Jain, A. Maghazachi, R. H. Goldfarb, and R. B. Herberman. 1989. Low deformability of lymphokine-activated killer cells as possible determinant of in vivo distribution. Cancer Res. 49:3742.
24. Papa, M. Z., J. J. Mule, and S. A. Rosenberg. 1986. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types. Cancer Res. 46:4973.
25. Spiess, P. J., J. Yang, and S. A. Rosenberg. 1987. In vivo antitumor activity of TIL expanded in recombinant IL-2. J. Natl. Cancer Inst. 79:1067.
26. Plautz, G. E., G. H. Barnett, D. W. Miller, B. H. Cohen, R. A. Prayson, J. C. Krauss, M. Luciano, D. B. Kangisser, and S. Shu. 1998. Systemic T cell adoptive immunotherapy of malignant gliomas. J. Neurosurg. 89:42.
27. Springer, T. A. 1994. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 76:301.
28. Spangrude, G. J., B. A. Braaten, and R. A. Daynes. 1984. Molecular mechanisms of lymphocyte extravasation I. Studies of two selective inhibitors of lymphocyte recirculation. J. Immunol. 132:354.
29. Ward, B. A., S. Shu, T. Chou, D. Perry-Lalley, and A. E. Chang. 1988. Cellular basis of immunologic interactions in adoptive T cell therapy of established metastases from a syngeneic murine sarcoma. J. Immunol. 141:1074.
30. 111Indium-labeled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy. Cancer 73:1731.